2nd Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Curr Pharm Des. 2018;24(5):641-646. doi: 10.2174/1381612824666180219145229.
Transcatheter aortic valve implantation (TAVI) is an increasingly common treatment of symptomatic severe aortic valve stenosis (AS). Thus, it is reasonable to carefully investigate the impact of individual clinical factors on outcomes after TAVI.
We aimed to investigate the impact of the previous cerebro-vascular events (CVEs) on outcomes of patients with severe AS undergoing TAVI.
A total of 148 consecutive patients scheduled for TAVI were included and stratified as with and without a history of CVEs (stroke or transient ischemic attack). Frailty features were also assessed. The primary endpoint was a 12-month all-cause mortality.
Seventeen (11.5%) patients had a history of CVEs (the CVE group). At 30 days and 12 months, all-cause mortality was higher in the CVE group [30-day: 5 (29.4%) vs. 7 (5.3%); p=0.005; 12-month: 9 (52.9%) vs. 13 (9.9%); p=0.001]. Similarly, at the longest available follow-up, mortality was higher in the CVE group [10 (58.8%) vs. 23 (17.6%); p=0.001]. Similar rates of other complications after TAVI were noted, apart from inhospital acute kidney injury (AKI) grade 3 [3 (17.6%) vs. 5 (3.8%); p=0.049] and blood transfusions [9 (52.9%) vs. 35 (26.7%); p=0.026]. Results of 5MWT and Katz index assessment indicated a greater level of frailty in the CVE group. There were no differences in subsequent events including CVEs, bleeding, myocardial infarction, and new-onset of atrial fibrillation (AF) at 12 months between the groups.
We showed that a history of CVEs in patients with severe AS undergoing TAVI is associated with a higher long-term mortality.
经导管主动脉瓣植入术(TAVI)是一种治疗症状性重度主动脉瓣狭窄(AS)的常用方法。因此,仔细研究个体临床因素对 TAVI 后结局的影响是合理的。
本研究旨在探讨既往脑血管事件(CVE)对重度 AS 患者行 TAVI 治疗结局的影响。
共纳入 148 例连续接受 TAVI 治疗的患者,并分为有和无 CVE(中风或短暂性脑缺血发作)病史两组。还评估了衰弱特征。主要终点是 12 个月全因死亡率。
17 例(11.5%)患者有 CVE 病史(CVE 组)。在 30 天和 12 个月时,CVE 组全因死亡率更高[30 天:5(29.4%)比 7(5.3%);p=0.005;12 个月:9(52.9%)比 13(9.9%);p=0.001]。同样,在最长随访期间,CVE 组死亡率更高[10(58.8%)比 23(17.6%);p=0.001]。除住院期间发生 3 级急性肾损伤(AKI)[3(17.6%)比 5(3.8%);p=0.049]和输血[9(52.9%)比 35(26.7%);p=0.026]外,两组之间 TAVI 后其他并发症的发生率相似。5MWT 和 Katz 指数评估结果表明 CVE 组患者的衰弱程度更高。两组在 12 个月时的后续事件(包括 CVE、出血、心肌梗死和新发心房颤动(AF))无差异。
我们发现,重度 AS 患者行 TAVI 治疗前有 CVE 史与长期死亡率增加相关。